Allogene Therapeutics
Mark DiMartino has extensive work experience in the field of quality data science. Mark is currently serving as the Executive Director of Quality Data Science at Allogene Therapeutics since October 2021. Prior to that, they worked at Amgen for several roles, including Lead Quality Data Science from May 2020 to October 2021, Director Quality Data Science from November 2017 to May 2020, Director Quality Engineering from December 2013 to November 2017, and Principle Quality Engineer from April 2011 to November 2013. Mark also worked at Abbott Diagnostics in various roles, including Senior Technical Support Scientist from February 2004 to February 2006, Analytical Quality Assurance Group Leader from December 2002 to February 2004, and Technical Support Scientist from February 2000 to December 2002.
Mark DiMartino received their Bachelor of Science degree in Cellular and Structural Biology from the University of Illinois Urbana-Champaign from 1994 to 1998. Mark later pursued a Master of Science degree in Applied Statistics at DePaul University from 2001 to 2004.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.